Ole Hauch

One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database.

ABSTRACT Objective: Acute coronary syndromes (ACS) are life-threatening disorders requiring intensive medical management or invasive cardiovascular procedures. Limited data exist on the costs and resource utilization associated with ACS. Methods: This retrospective single-cohort study analyzed administrative claims data from employer-sponsored plans for patients with an ACS hospitalization in 2001–2002. A 1‑year follow-up period was used, and patients who were under age 35 or had an ACS diagnosis in the 12 months before the hospitalization were excluded. Costs were reported in 2005 US dollars. Results: We identified 16 321 patients hospitalized for ACS during the study period. Mean (± SD) age was 55.6 (± 6.7) years, 66.7% were male, and 46.3% underwent a revascularization procedure during their initial hospitalization. Mean length of stay for the initial hospitalization was 4.6 days (median: 3.0; IQR: 2.0–5.0), and per-patient expenditures averaged

Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study

22 921 (median:

Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.

13 960; IQR:

Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice

6839–28 588). During the follow-up period, 21% of patients were rehospitalized for ischemic heart disease (IHD), and the cost of rehospitalization averaged

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting

28 637. Additionally, in the year following the inpatient admission, 50% of patients were prescribed antiplatelet or anticoagulant medications, and 90% of patients were prescribed lipid-lowering, antihypertensive, or antiarrhythmic medications. IHD-related expenditures after the initial inpatient stay averaged

Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs

9425 (median:

A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation.

2800; IQR:

Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.

899–7577); 61% of these costs were due to rehospitalization. Total first-year costs averaged

Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care

32 345 (median:

Monitoring anticoagulation in atrial fibrillation

21 653; IQR: